Filing Flows › Regenerative Medical Technology Group (RMTG) › Q2 2026
Regenerative Medical Technology Group (RMTG) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 19, 2026
Regenerative Medical Technology Group (RMTG) reported revenue of $4.0M for the second quarter 2026 (Q2 2026), +309% from a year earlier and +52% from the quarter before. Operating margin was 14.1%, net loss $2.9M (72.2% of revenue).
Regenerative Medical Technology Group, Q2 2026: revenue $4.0M (+309% year over year), operating margin 14.1%, net loss $2.9M, operating cash flow $332K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.0M | +52% | +309% |
| Operating profit | $566K | +146% | — |
| Net earnings | −$2.9M | — | — |
| Operating cash flow | $332K | +225% | — |
| Free cash flow | $288K | — | — |
What changed
Revenue was $4.0M in Q2 2026, up 309% year over year and up 52% from the previous quarter.
Gross margin was 64.1%, up 4.5 points from Q2 2025. Operating profit was $566K, a 14.1% margin (up 39.5 points year over year). Operating expenses grew 141% against revenue growth of 309%. The fastest-growing cost line was Sales & marketing (+270%). The quarter ended with a net loss of $2.9M, wider than the previous quarter's $876K loss. Net interest and other expense of $3.5M was the main reason.
Operating cash flow was $332K. Non-cash charges added back $91K of depreciation and amortization. Working capital and other items added $3.1M. Capital expenditures of $43K left free cash flow of $288K.
Questions
What was Regenerative Medical Technology Group's revenue in the second quarter 2026?
Regenerative Medical Technology Group (RMTG) reported revenue of $4.0M for the second quarter 2026 (Q2 2026), +309% from a year earlier and +52% from the quarter before.
Was Regenerative Medical Technology Group profitable in the second quarter 2026?
Operating profit was $566K (14.1% of revenue) and net loss $2.9M.
Source: Regenerative Medical Technology Group 10-Q on SEC EDGAR.